IRIS
CASCINU, STEFANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.678
AS - Asia 7.128
NA - Nord America 4.828
SA - Sud America 2.263
AF - Africa 181
Continente sconosciuto - Info sul continente non disponibili 16
OC - Oceania 10
AN - Antartide 1
Totale 22.105
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.607
RU - Federazione Russa 4.472
SG - Singapore 2.564
CN - Cina 2.088
BR - Brasile 1.876
HK - Hong Kong 1.032
VN - Vietnam 822
SE - Svezia 782
IT - Italia 591
RO - Romania 550
FR - Francia 381
DE - Germania 270
AR - Argentina 164
GB - Regno Unito 152
IN - India 126
FI - Finlandia 118
MX - Messico 90
BD - Bangladesh 89
CA - Canada 86
ID - Indonesia 72
ZA - Sudafrica 70
AT - Austria 64
EC - Ecuador 62
NL - Olanda 57
PL - Polonia 54
ES - Italia 52
TR - Turchia 47
IQ - Iraq 45
JP - Giappone 44
CO - Colombia 42
IE - Irlanda 31
VE - Venezuela 30
UA - Ucraina 28
CL - Cile 26
MA - Marocco 26
PY - Paraguay 26
UZ - Uzbekistan 25
PK - Pakistan 24
EG - Egitto 22
LT - Lituania 17
SA - Arabia Saudita 17
IR - Iran 16
KE - Kenya 16
UY - Uruguay 16
PE - Perù 15
TN - Tunisia 14
AE - Emirati Arabi Uniti 13
AL - Albania 11
DZ - Algeria 11
JO - Giordania 11
AU - Australia 10
AZ - Azerbaigian 10
NP - Nepal 10
EU - Europa 9
IL - Israele 9
OM - Oman 8
AO - Angola 7
BY - Bielorussia 7
PH - Filippine 7
HN - Honduras 6
JM - Giamaica 6
KZ - Kazakistan 6
LB - Libano 6
MY - Malesia 6
PT - Portogallo 6
BE - Belgio 5
BO - Bolivia 5
CR - Costa Rica 5
TH - Thailandia 5
BB - Barbados 4
MD - Moldavia 4
NI - Nicaragua 4
PA - Panama 4
PS - Palestinian Territory 4
XK - ???statistics.table.value.countryCode.XK??? 4
CH - Svizzera 3
CZ - Repubblica Ceca 3
DO - Repubblica Dominicana 3
ET - Etiopia 3
GA - Gabon 3
HR - Croazia 3
KG - Kirghizistan 3
KW - Kuwait 3
PR - Porto Rico 3
SN - Senegal 3
TT - Trinidad e Tobago 3
TW - Taiwan 3
A1 - Anonimo 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BM - Bermuda 2
CI - Costa d'Avorio 2
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
GR - Grecia 2
GT - Guatemala 2
HU - Ungheria 2
KR - Corea 2
MK - Macedonia 2
Totale 22.083
Salva come PNG Salva come JPEG
Città #
Dallas 1.259
Singapore 1.182
Moscow 1.062
Hong Kong 1.024
Ashburn 587
San Jose 456
Shanghai 399
Hefei 367
Ho Chi Minh City 329
Lauterbourg 321
Lawrence 314
Princeton 313
Beijing 288
New York 206
São Paulo 170
Hanoi 152
Los Angeles 134
Helsinki 95
Milan 95
Boardman 71
Rome 70
Nuremberg 69
Munich 67
Rio de Janeiro 59
Orem 58
Santa Clara 56
Warsaw 49
Guangzhou 44
Haiphong 43
Tokyo 40
Belo Horizonte 36
Chennai 34
Denver 34
Stockholm 33
Brasília 32
Cesano Boscone 32
Poplar 32
Chicago 31
Montreal 31
Vienna 31
Da Nang 30
Dublin 30
Johannesburg 30
Brooklyn 29
London 28
Porto Alegre 28
Houston 26
The Dalles 26
Mexico City 25
Curitiba 24
Frankfurt am Main 24
Tashkent 24
Campinas 23
Guayaquil 23
Manchester 23
Amsterdam 21
Ankara 21
Phoenix 21
Ribeirão Preto 21
Toronto 21
Guarulhos 20
Atlanta 19
Biên Hòa 19
Boston 19
Columbus 19
Quito 19
Thái Bình 19
Council Bluffs 18
Tianjin 18
Baghdad 17
Dhaka 17
Mumbai 17
Buenos Aires 16
Cape Town 16
Salvador 16
Hortolândia 15
Montevideo 15
Shenzhen 15
Hải Dương 14
Nairobi 14
Recife 14
Turku 14
Blumenau 13
Fortaleza 13
Querétaro 13
Contagem 12
Duque de Caxias 12
Manaus 12
Naples 12
Santo André 12
Seattle 12
Asunción 11
Brescia 11
Cairo 11
Jakarta 11
Lima 11
Niterói 11
Pelotas 11
Sumaré 11
Volta Redonda 11
Totale 10.783
Salva come PNG Salva come JPEG
Nome #
Delphi Initiative for Early-Onset Colorectal Cancer (DIRECt) International Management Guidelines 428
Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab 424
Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study 417
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study 343
Exploring machine learning tools in a retrospective case-study of patients with metastatic non-small cell lung cancer treated with first-line immunotherapy: A feasibility single-centre experience 182
Advanced Digestive Neuroendocrine Tumors Metastatic Pattern Is an Independent Factor Affecting Clinical Outcome 121
Impact of body mass index on the prognosis of unresectable HCC patients receiving first-line Lenvatinib or atezolizumab plus bevacizumab 115
DIET AND LIFESTYLE HABITS IN EARLY-ONSET COLORECTAL CANCER. A PILOT CASE-CONTROL STUDY 115
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 115
Combined Loco-Regional and Systemic Treatment Strategies for Hepatocellular Carcinoma: From Basics to New Developments 111
Addressing the challenges of pancreatic cancer: Future directions for improving outcomes 110
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib 110
Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab 109
Early integration of palliative care in oncology practice: Results of the Italian Association of Medical Oncology (AIOM) survey 109
Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population 108
A randomized, double blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel 108
Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer – A GISCAD phase II randomized trial 108
Definitions and treatment of oligometastatic oesophagogastric cancer according to multidisciplinary tumour boards in Europe 108
Emergency Department Visits among Cancer Patients during SARS-CoV-2 Pandemic 106
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patients 104
Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients 103
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 103
Germline testing and genetic counseling in biliary tract cancer: an operative proposal to improve the state of art 102
Radial and longitudinal margins in surgery of perihilar cholangiocarcinoma: When R1 definition is associated with different prognosis 101
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX 101
Does immunotherapy change the treatment paradigm in metastatic gastric cancer? 100
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinoma 98
Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study 98
Metabolism and immune modulation in patients with solid tumors: Systematic review of preclinical and clinical evidence 98
Role of stereotactic radiosurgery for the treatment of brain metastasis in the era of immunotherapy: A systematic review on current evidences and predicting factors 98
Atezolizumab plus bevacizumab versus Lenvatinib for patients with Barcelona clinic liver cancer stage B (BCLC-B) hepatocellular carcinoma (HCC): A real-world population 97
A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors 97
Prediction of early distant recurrence in upfront resectable pancreatic adenocarcinoma: A multidisciplinary, machine learning-based approach 97
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 95
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients 95
Early intravenous administration of nutritional support (IVANS) in metastatic gastric cancer patients at nutritional risk, undergoing first-line chemotherapy: study protocol of a pragmatic, randomized, multicenter, clinical trial 94
Pre-existing immunity drives the response to neoadjuvant chemotherapy in esophageal adenocarcinoma 92
Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes 91
Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study 91
Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma 91
Aflibercept, a New Way to Target Angiogenesis in the Second Line Treatment of Metastatic Colorectal Cancer (mCRC) 91
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy 91
Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma 90
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme 90
Adjuvant chemotherapy in colon cancer: can we improve quality of care? 89
A phase II study of the L19IL2 immunocytokine in combination with dacarbazine in advanced metastatic melanoma patients 88
An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) + gemcitabine vs gemcitabine alone for metastatic pancreatic cancer patients: the APICE study 88
A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer 87
A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor 87
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW 87
Cholangiocarcinoma: new perspectives for new horizons 87
Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients 87
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 86
Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE-2 Study 86
Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey 86
Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives 85
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma? 85
HER2 Pathway in Biliary Tract Cancer: A Snapshot of the Current Understanding and Future Directions 84
ANGPT2 and NOS3 polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients receiving sorafenib 84
5-Fluorouracil pharmacogenomics: still rocking after all these years? 84
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 83
Different Genomic Clusters Impact on Responses in Advanced Biliary Tract Cancer Treated with Cisplatin Plus Gemcitabine Plus Durvalumab 83
A Novel Prognostic Tool in Western and Eastern Biliary Tract Cancer Patients Treated in First-line Setting: the ECSIPOT Index 82
Allele polymorphisms of tumor integrins correlate with peritoneal carcinosis capability of gastric cancer cells in radically resected patients 81
A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study 81
Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients 81
A Dose-finding and Biomarker Evaluation Phase Ib Study of Everolimus in Association With 5-Fluorouracil and Pelvic Radiotherapy as Neoadjuvant Treatment of Locally Advanced Rectal Cancer (E-LARC Study) 80
The evolving role of microsatellite instability in colorectal cancer: A review 79
The role of anti-angiogenics in pre-treated metastatic BRAF-mutant colorectal cancer: A pooled analysis 79
Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters 78
[11C]-Methionine Positron Emission Tomography in the Postoperative Imaging and Followup of Patients with Primary and Recurrent Gliomas 78
To resect or not to resect: The hamletic dilemma of primary tumor resection in patients with asymptomatic stage IV colorectal cancer 78
Identification of Regorafenib Prognostic Index (REP Index) via Recursive Partitioning Analysis in Patients with Advanced Hepatocellular Carcinoma Receiving Systemic Treatment: A Real-World Multi-Institutional Experience 78
Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab 77
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 76
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 74
α-FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma 73
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 73
Corrigendum to ‘Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic cholangiocarcinoma’ [Euro J Cancer 171 (2022) 232–241, (S0959804922002829), (10.1016/j.ejca.2022.05.004)] 72
BRAF-mutated colorectal cancer: Clinical and molecular insights 72
Is there a role for chemotherapy after local relapse in high-grade osteosarcoma? 72
Past, present, and future of FGFR inhibitors in cholangiocarcinoma: from biological mechanisms to clinical applications 70
Panitumumab in combination with infusional oxaliplatin and oral capecitabine for conversion therapy in patients with colon cancer and advanced liver metastases. The MetaPan study 70
The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy 70
Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma: Ready for Prime Time? 70
Il ruolo della radiochirurgia stereotassica nel trattamento delle metastasi cerebrali nell’era dell’immunoterapia: una revisione sistematica sulle evidenze attuali e sui fattori predittivi. 69
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 69
Survival Outcomes of Durvalumab in Combination with Cisplatin and Gemcitabine in Advanced Biliary Tract Cancer: Real-World Results from a Single Italian Institution 68
The role of 18F-FAZA PET/CT in detecting lymph node metastases in renal cell carcinoma patients: a prospective pilot trial 67
Anti-HER2 therapies in biliary tract cancers: A meta-analysis on disease location, HER2 status, and survival outcomes 66
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 66
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 66
Il ruolo della radiochirurgia stereotassica nel trattamento delle metastasi cerebrali nell’era dell’immunoterapia: una revisione sistematica sulle evidenze attuali e sui fattori predittivi 65
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study 65
Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery 65
The prognostic value of the new combined hemo-eosinophil inflammation index (Hei index): A multicenter analysis of anal cancer patients treated with concurrent chemo-radiation 65
Heavily calcified gastrointestinal stromal tumors: Pathophysiology and implications of a rare clinicopathologic entity 64
Real Life Study of Lenvatinib Therapy for Hepatocellular Carcinoma: RELEVANT Study 63
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants 63
Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib 63
Totale 10.029
Salva come PNG Salva come JPEG
Categoria #
all - tutte 140.152
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 140.152
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 0 0 0 0 1 0
2021/2022229 0 1 0 99 7 7 23 43 19 7 6 17
2022/20231.524 736 283 86 8 13 201 41 73 59 6 10 8
2023/2024684 23 38 88 84 43 148 11 61 9 28 46 105
2024/20255.209 624 116 62 58 94 428 1.068 459 831 774 304 391
2025/202614.699 1.098 1.505 1.452 2.200 1.126 540 1.179 1.079 4.012 508 0 0
Totale 22.616